Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UTS2R | Q9UKP6 | 2/20 | 0.51 |
| ▸ | HTR2C | P28335 | 2/20 | 0.47 |
| ▸ | HTR2B | P41595 | 2/20 | 0.47 |
| ▸ | SSTR1 | P30872 | 1/20 | 0.46 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.46 |
| ▸ | NOS3 | P29474 | 1/20 | 0.46 |
| ▸ | NOS1 | P29475 | 1/20 | 0.46 |
| ▸ | NOS2 | P35228 | 1/20 | 0.46 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.46 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.46 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.46 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1929245 | 0.92 | SMN1; SMN2 (0.51) | UTS2RSSTR1SSTR4CHRM4CHRM5 | |
| SCHEMBL14578204 | 0.83 | HTR2C (0.53) | HTR2CHTR2BNOS3NOS1NOS2 | |
| SCHEMBL1926949 | 0.81 | HRH3 (0.43) | — | |
| SCHEMBL1926800 | 0.81 | ALDH1A1 (0.46) | UTS2RCHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL10260935 | 0.81 | PDE10A (0.51) | HTR2CHTR2BNOS3NOS1NOS2 | |
| SCHEMBL10260949 | 0.81 | PDE10A (0.51) | HTR2CHTR2BNOS3NOS1NOS2 | |
| SCHEMBL15062004 | 0.81 | PDE10A (0.51) | HTR2CHTR2BNOS3NOS1NOS2 | |
| SCHEMBL1928080 | 0.81 | SCD (0.37) | UTS2RSSTR1SSTR4CHRM4CHRM5 | |
| SCHEMBL1926914 | 0.80 | LMNA (0.42) | UTS2RSSTR1SSTR4 | |
| SCHEMBL15651062 | 0.80 | NOS3 (0.52) | HTR2CHTR2BNOS3NOS1NOS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110152234-A1 | Novel Compounds | ASTRAZENECA AB (SE) | 2011-06-23 | — | — | US | disclosed |
| US-7956084-B2 | Phenyl thiophene carboxamide compounds as inhibitors of the enzyme IKK-2 | ASTRAZENECA AB (SE) | 2011-06-07 | — | — | US | disclosed |
| EP-1421074-B1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2010-09-29 | — | — | EP | disclosed |
| US-20070015819-A1 | Novel compounds | ASTRAZENECA AB, A SWEDEN CORPORATION | 2007-01-18 | — | — | US | disclosed |
| US-7125896-B2 | Thiophene carboxamide compounds as inhibitors of enzyme IKK-2 | ASTRAZENECA AB (SE) | 2006-10-24 | — | — | US | disclosed |
| US-20040242573-A1 | Novel compounds | ASTRAZENECA AB (SE) | 2004-12-02 | — | — | US | disclosed |
| EP-1421074-A1 | NOVEL COMPOUNDS | AstraZeneca AB (SE) | 2004-05-26 | — | — | EP | disclosed |
| WO-2003010158-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2003-02-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070015819-A1 | Novel compounds | CNR1, ABCG2, CNR2 | UTS2R 553/4885HTR2C 186/4885HTR2B 201/4885 |
| US-20040242573-A1 | Novel compounds | SULT1E1, TPMT, UGT1A1 | UTS2R 778/4885HTR2C 284/4885HTR2B 555/4885 |
| US-20110152234-A1 | Novel Compounds | CNR1, ABCG2, CNR2 | UTS2R 553/4885HTR2C 186/4885HTR2B 201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.